Biotech Sector Update FDA Prostate Cancer Drug to Include Warning Update

www.StockMarketFunding.com FDA confirms that it asked drug manufacturers to include warnings on risk for class of prostate cancer drugs. The US Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer. The warnings would alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications. GnRH agnoists are marketed under the brand names Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex. Several generic products are available. (SGEN, MIPI, RNN, OGXI, DNDN, ISIS, ISR, MYGN, MDVN, PFE, AZN)

Thanks To : Wireless baby monitor Baby strollers Best Polarized sunglass